SCIENTIFIC LITERATURE · MED

A community-led initiative to de-risk and advance Parkinson's disease therapeutic targets.

Vaiana A, Behr J, Birol R, Blauwendraat C, Casey B, Chowdhury K, Citron M, Crapser J, Dardov V, Ducotterd F, Dumanis S, Dunlop J, Durborow M, Fiske B, Golden J, Hannestad J, Hung W, Kemp J, Kleiman R, Knight A, Koemeter-Cox A, Leuchter B, Logsdon BA, Marreiros R, Miller JE, Mitchell A, Mukherjee P, Navarro G, Nelson MR, Nikolich K, Otis T, Polinski N, Rastegar-Pouyani S, Reith AD, Riley E, Rubin L, Ryten M, Sadick J, Schwabe T, Sherer T, Silvergleid S, Singleton A, St Clair L, Stoehr J, Stone DJ, Sullivan J, Tanenbaum N, Tinelli E, Trimble K, Wang Y, Weninger S, Wiggenhauser N, Wood S, Schoepp D, Buggia-Prevot V, Padmanabhan S, Skibinski G.

NPJ Parkinsons Dis · 2025-06-20

DOI: 10.1038/s41531-025-01039-3PMID: 40541945

Open accessreview-article; Review; Journal ArticleOriginal source ↗

Research overview

The text below is the source article’s original abstract under a verified reuse license. cc by

Identifying effective therapeutic targets for Parkinson's disease (PD) is challenging, with no current disease-modifying therapies available. To address this, The Michael J. Fox Foundation for Parkinson's Research launched the Targets to Therapies (T2T) initiative, uniting experts to prioritize and validate promising targets. T2T aims to develop validation strategies, create comprehensive target data profiles, and build tools to support drug development, ultimately accelerating the discovery of new therapies for PD patients.

Scientific assessment

Research question

Assess the question within the original study’s scope.

Methods & sample

Check the source article for study design and sample details.

Key findings

An editorially approved findings summary is not yet published for this record.

Limitations

Generalizability, bias and clinical meaning require separate assessment.

Methods, samples and clinical conclusions are not inferred from bibliographic metadata.